Benzonatate Refill in COPD: Not Recommended
Benzonatate should not be refilled for this patient, as it is not indicated for COPD management and provides no benefit for chronic cough in COPD patients. 12
Why Benzonatate Is Inappropriate for COPD
Benzonatate is a non-narcotic antitussive that temporarily suppresses cough reflex, but it has no role in evidence-based COPD pharmacotherapy. The 2023 Canadian Thoracic Society guideline and 2011 multi-society COPD guidelines make no mention of antitussive therapy because cough suppression does not address the underlying pathophysiology of COPD—airflow obstruction, inflammation, and exacerbation risk 12.
Key Problems with Benzonatate in This Population:
- No disease-modifying effect: Does not improve lung function, reduce exacerbations, or affect mortality/morbidity in COPD
- Safety concerns in elderly: Significant risk of serious adverse events including seizures (1%), cardiac dysrhythmias (0.4%), and cardiac arrest (0.3%), with 35% of serious outcomes occurring in vulnerable populations 3
- Overdose risk: Even therapeutic doses near 200 mg can produce serious outcomes; the drug has caused fatalities from dysrhythmias 43
What This Patient Actually Needs
Instead of refilling benzonatate, reassess and optimize evidence-based COPD pharmacotherapy:
1. Confirm Current Inhaled Bronchodilator Therapy
- For symptomatic COPD patients, inhaled bronchodilators are the cornerstone of treatment 2
- Long-acting anticholinergics (LAMA) or long-acting beta-agonists (LABA) as monotherapy are strongly recommended 2
- Combination therapy (LAMA/LABA or addition of inhaled corticosteroids) may be considered for persistent symptoms 2
2. Evaluate Inhaler Technique
- Critical in elderly patients: 60-80% of older COPD patients use inhalers incorrectly 5
- Assess inspiratory flow capacity, cognition, and coordination 5
- If inadequate technique, consider device change or nebulized alternatives
3. Address the Cough Appropriately
- Chronic cough in COPD responds to optimized bronchodilator therapy, not antitussives
- Evaluate for COPD exacerbation, post-nasal drip, GERD, or ACE inhibitor use
- Consider pulmonary rehabilitation if FEV1 <50% predicted 2
4. Assess for Exacerbation Risk Factors
- Review vaccination status (influenza, pneumococcal)
- Ensure smoking cessation counseling if applicable
- Evaluate for comorbidities (heart failure can mimic COPD symptoms) 2
Clinical Pitfalls to Avoid
- Do not assume cough requires antitussive therapy: In COPD, cough is a symptom of the underlying disease requiring disease-directed treatment
- Do not overlook medication reconciliation: The patient stopped benzonatate for a reason—explore why and whether COPD therapy was also discontinued
- Do not prescribe benzonatate "as needed": The FDA label indicates dosing up to 600 mg daily 6, but this provides no therapeutic benefit for COPD and increases toxicity risk in an 84-year-old
Practical Recommendation
Contact the patient to schedule a visit or telehealth appointment to:
- Assess current COPD symptoms and control
- Review and optimize maintenance inhaler therapy
- Verify proper inhaler technique
- Evaluate need for pulmonary rehabilitation referral
- Explain why benzonatate is not appropriate for COPD management
If the patient insists on cough suppression while awaiting optimization of COPD therapy, consider safer alternatives like guaifenesin, but emphasize that definitive management requires addressing the underlying COPD with evidence-based bronchodilator therapy 12.